Ligand Pharmaceuticals vs MacroGenics
LGND and MGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGND and MGNX compare
Ligand Pharmaceuticals is the larger company, worth 45 times as much as MacroGenics ($5.9B against $131M).
MacroGenics grew revenue faster over the last twelve months (11.7% versus 1.0% for Ligand Pharmaceuticals).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −8.7% at MacroGenics.
Ligand Pharmaceuticals scores higher on the StockData Score (6 against 5 for MacroGenics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGND | MGNX |
|---|---|---|
| Size and price | ||
| Market cap | $5.9B | $131M |
| Share price | $293.81 | $2.05 |
| Change, 1 year | 46.3% | 36.7% |
| Change, 5 years | 87.3% | −89.1% |
| Beta (5Y) | 0.84 | 0.53 |
| Employees | 47 | 293 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 128× | – |
| P/S | 23.2× | 0.8× (better) |
| P/B | 6.1× | 3.0× (better) |
| EV/EBITDA | 108× | – |
| P/FCF | 64.8× | – |
| FCF yield | 1.5% (better) | −50.2% |
| Fair value | $55.15 | – |
| Margin of safety | −433% | – |
| Growth | ||
| Revenue growth (TTM) | 1.0% | 11.7% (better) |
| Revenue growth, 5Y average | 10.4% (better) | 7.3% |
| Net income growth (TTM) | 5.9% | – |
| EPS growth (TTM) | 18.7% | – |
| Profitability | ||
| Operating margin | 10.1% (better) | −24.3% |
| Net margin | 20.3% (better) | −8.7% |
| FCF margin | 35.7% (better) | −39.1% |
| Return on equity | 5.4% (better) | −32.6% |
| Return on invested capital | 2.6% | – |
| Financial health | ||
| Debt / equity | 1.17 | – |
| Net debt / EBITDA | 11.26 | – |
| Interest coverage | 3.1× (better) | −2.4× |
| Current ratio | 1.22 | 2.96 (better) |
| Altman Z-score | 3.32 (better) | −4.02 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 113% | 76.4% |
| Held by insiders | 2.6% | 6.2% |
| Insider net buying, 12 months | −$36.5M | −$129K (better) |
| Short interest, % of float | – | 8.3% |
Go deeper
- LGND stock overview
- LGND income statement
- LGND valuation and score
- MGNX stock overview
- MGNX income statement
- MGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.